Statins are the choice of drugs for the treatment and management of hypercholesterolaemia
because of their established lipid-lowering efficacy and safety profile. Among the various statins, simvastatin
is a very popular antihyperlipidemic drug with pleiotropic effects that have a wide range of applications
such as antioxidant, anti-inflammatory, antifibrotic effect as well as angiogenic activity.
However, poor biopharmaceutical characteristics like low solubility and high permeability make this
drug more challenging for formulation scientists in terms its delivery to different targeted areas. Oral
drug delivery systems, lipid nanoparticles, PLGA nanoparticles, sustained-release tablets, matrix-type
transdermal, co-encapsulating nanostructured lipid carriers are some of the strategies that have been
explored to address this issue. This review provides an update regarding the disease, destination, dose
and delivery associated with this wonderful lipid-lowering drug molecule.
Keywords: Simvastatin, hyperlipidemia, HMG-CoA reductase, cholesterol, cardiovascular disease, drug delivery approaches,
Rights & PermissionsPrintExport